Table 1.
Demographics and clinical characteristics of Behçet’s disease (BD) patients
| Parameter | Value |
|---|---|
| Age (years), mean ± SD | 35.83 ± 11.96 |
| Age at BD diagnosis (years), median (range) | 28.5 (17–60) |
| Disease duration (months), median (range) | 120(13–379) |
| BDCAF, median (range) | 10 (3–33) |
| Clinical features of BD | |
| Oral ulcer | 24 (100%) |
| Genital ulcer | 17 (70.8%) |
| Skin lesions | 16 (66.7%) |
| Ocular lesions | 8 (33.3%) |
| Vascular involvement | 7 (29.2%) |
| Pathergy reaction | 5 (20.8%) |
| Gastrointestinal involvement | 3 (12.5%) |
| Neurologic involvement | 1 (4.2%) |
| Erythrocyte sedimentation rate (mm/h), median (range) | 15.5 (2–76) |
| C-reactive protein (mg/L), median (range) | 9.62 (0.56–53.1) |
| Treatment-naive | 7 (29.2%) |
| Current medications | |
| Glucocorticoid | 15 (62.5%) |
| Thalidomide | 13 (54.2%) |
| Cyclophosphamide | 11 (45.8%) |
| Salazosulfapyridine | 3 (12.5%) |
| Cyclosporine A | 2 (8.3%) |
| Methotrexate | 2(8.3%) |
| Azathioprine | 1 (4.2%) |
| Etanercept | 1 (4.2%) |
Values are shown as n (%) unless otherwise indicated
BDCAF Behçet’s Disease Current Activity Form